Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Total Current Liabilities (2016 - 2025)

Enanta Pharmaceuticals' Total Current Liabilities history spans 14 years, with the latest figure at $44.7 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 8.81% year-over-year to $44.7 million; the TTM value through Dec 2025 reached $44.7 million, down 8.81%, while the annual FY2025 figure was $48.6 million, 15.61% down from the prior year.
  • Total Current Liabilities reached $44.7 million in Q4 2025 per ENTA's latest filing, down from $48.6 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $68.2 million in Q2 2023 to a low of $23.0 million in Q4 2022.
  • Average Total Current Liabilities over 5 years is $43.2 million, with a median of $44.6 million recorded in 2025.
  • Peak YoY movement for Total Current Liabilities: plummeted 39.3% in 2022, then skyrocketed 196.02% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $37.9 million in 2021, then tumbled by 39.3% to $23.0 million in 2022, then soared by 171.32% to $62.4 million in 2023, then fell by 21.4% to $49.0 million in 2024, then fell by 8.81% to $44.7 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Total Current Liabilities are $44.7 million (Q4 2025), $48.6 million (Q3 2025), and $44.5 million (Q2 2025).